Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2A study of OTP-01 in advanced solid tumors
2025-524111-37-00Phase 2Authorised
- Sponsor
- Ottimo Pharma
- Start
- Apr 2026
- Modality
- Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of OTP-01 in Nonhematologic neoplasms (2 arms), sponsored by Ottimo Pharma. Primary endpoints: Safety, tolerability, biologic activity, pharmacokinetics, pharmacodynamics, and preliminary efficacy, Adverse events and serious adverse events and 4 more. Planned start Apr 2026; status: authorised.
02
Drugs
OTP-01
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-524111-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524111-37-00.